Oktay Ayse Nur, Polli James E
Department of Pharmaceutical Sciences, University of Maryland, 20 Penn Street, Baltimore, MD 21201, USA; Gulhane Faculty of Pharmacy, Department of Pharmaceutical Technology, University of Health Sciences, Ankara, Turkey.
Department of Pharmaceutical Sciences, University of Maryland, 20 Penn Street, Baltimore, MD 21201, USA.
Eur J Pharm Sci. 2024 May 1;196:106746. doi: 10.1016/j.ejps.2024.106746. Epub 2024 Mar 16.
We understand that quality control dissolution media may best anticipate in vivo product performance by mimicking in vivo media, but preferably involve at most a single pharmaceutical surfactant for routine laboratory use. The objective here was to estimate the concentrations of six pharmaceutical surfactants to mimic etravirine solubility and intrinsic dissolution rate, as well as dissolution rate from a film model, in each Fed State Simulated Intestinal Fluid Version 2 (FeSSIF-V2) and Fasted State Simulated Intestinal Fluid Version 2 (FaSSIF-V2). Solubility studies and colloid sizing measurements were conducted. Results indicate that all six surfactants were more efficient than FeSSIF-V2 or FaSSIF-V2 at solubilizing drug, and also exhibited higher micelle diffusivities than FeSSIF-V2 and FaSSIF-V2 mixed-micelles. The rank-order potency (on mM basis) of the six pharmaceutical surfactants to mimic etravirine solubility in each FeSSIF-V2 and FaSSIF-V2 was: polysorbate 80 (PS80) > polysorbate 20 (PS20) > polyoxyethylene(23) lauryl ether (POE23) > POE10 > hexadecyltrimethylammonium bromide (HEX) > sodium lauryl sulfate (SLS). This rank-order potency was almost the same to mimic drug dissolution rate into each FeSSIF-V2 and FaSSIF-V2, except POE10 > POE23. For the most potent surfactant, PS80, 0.461 mM and 0.140 mM PS80 was estimated to mimic etravirine's solubility and dissolution rate into FeSSIF-V2, respectively, using the intrinsic dissolution model. The low PS80 concentration to mimic dissolution rate reflects the relatively high diffusivity of PS80 micelles, compared to FeSSIF-V2 mixed-micelle diffusivity, which was the case for all six pharmaceutical surfactants. Results are also presented in terms of a film dissolution model for surfactant-mediated dissolution, where dissolution enhancement was less than that in the intrinsic dissolution model, and the film model required lower surfactant concentration than in intrinsic dissolution model to mimic FeSSIF-V2-enhanced dissolution. Findings have promised to identify single pharmaceutical surfactant concentrations that mimic key performance attributes of biorelevant media.
我们明白,质量控制溶出介质通过模拟体内介质可能最能预测体内产品性能,但对于常规实验室使用而言,最好最多只涉及一种药用表面活性剂。此处的目的是估计六种药用表面活性剂在每种进食状态模拟肠液版本2(FeSSIF-V2)和空腹状态模拟肠液版本2(FaSSIF-V2)中的浓度,以模拟依曲韦林的溶解度、固有溶出速率以及从膜模型的溶出速率。进行了溶解度研究和胶体粒径测量。结果表明,所有六种表面活性剂在溶解药物方面都比FeSSIF-V2或FaSSIF-V2更有效,并且其胶束扩散率也高于FeSSIF-V2和FaSSIF-V2的混合胶束。六种药用表面活性剂在每种FeSSIF-V2和FaSSIF-V2中模拟依曲韦林溶解度的效价排序(以毫摩尔为单位)为:聚山梨酯80(PS80)>聚山梨酯20(PS20)>聚氧乙烯(23)月桂醚(POE23)>POE10>十六烷基三甲基溴化铵(HEX)>十二烷基硫酸钠(SLS)。除了POE10>POE23外,这种效价排序在模拟药物在每种FeSSIF-V2和FaSSIF-V2中的溶出速率时几乎相同。对于最有效的表面活性剂PS80,使用固有溶出模型估计,分别有0.461 mM和0.140 mM的PS80可模拟依曲韦林在FeSSIF-V2中的溶解度和溶出速率。与FeSSIF-V2混合胶束扩散率相比,模拟溶出速率所需的低PS80浓度反映了PS80胶束相对较高的扩散率,所有六种药用表面活性剂均是如此。还根据表面活性剂介导溶出的膜溶出模型给出了结果,其中溶出增强小于固有溶出模型中的情况,并且膜模型模拟FeSSIF-V2增强溶出所需的表面活性剂浓度低于固有溶出模型。这些发现有望确定模拟生物相关介质关键性能属性的单一药用表面活性剂浓度。